Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Therapeutic advances in the management of IBD have led to a paradigm shift in the
assessment of IBD disease activity. Beyond clinical remission, objective assessment of …

Background: The contemporary management of ambulatory ulcerative colitis (UC) continues
to be challenging with∼ 20% of children needing a colectomy within childhood years. We …

Clinically effective therapies now exist for remission maintenance in both ulcerative colitis
[UC] and Crohn's Disease [CD]. For each major class of IBD medications [5 …

This ECCO topical review of the European Crohn's and Colitis Organisation [ECCO] focuses
on the epidemiology, pathophysiology, diagnosis, management and outcome of the two …

Little is known about the optimal duration of therapy with an anti–tumor necrosis factor (TNF)
agent and/or an immunomodulator for patients with inflammatory bowel disease (IBD). We …

Treatment strategies for inflammatory bowel disease (IBD) focus on the induction and long-
term maintenance of deep remission to avoid complications of active disease and improve …

Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are
immunomodulating agents primarily used to maintain corticosteroid-free remission in …

Background We aimed to develop criteria for treatment intensification in patients with (1)
luminal Crohn's disease (CD),(2) CD with perianal disease and/or fistula,(3) CD with small …

Background Management of inflammatory bowel disease (IBD) has evolved in the last
decade. Aim To assess IBD therapeutic management, including treatment withdrawal and …